We need to break free from the idea that giving to women’s advancement is a subtraction. Instead, we need to see advancing women as an intentional multiplication that benefits teams, organisations, ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...

GSK has signed an eleventh-hour agreement to give Alfasigma rights to its primary biliary cholangitis (PBC) therapy ...

The opening months of 2026 painted a vivid picture of a life sciences sector in rapid motion, stretched between scientific ...

The two companies announced today that Hims & Hers will now be able to sell Novo Nordisk's injectable and oral semaglutide products, sold respectively as Ozempic for type 2 diabetes and Wegovy for ...

Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...

Prasad was first appointed head of the FDA's Center for Biologics Evaluation and Research (CBER) in May 2025 – after his ...

STEM has spent nearly two decades supporting pharma companies with strategic insights. As Adam Boucher explained, the emergence of generative AI has opened new possibilities for analysing field ...

Daiichi Sankyo's European division has signed a partnership with German digital health company GAIA to sell a digital ...

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A ...